NeutriSci International hat mit NeuEnergy "a smarter energy choice" - kann RedBull einpack (Seite 615)
eröffnet am 03.09.15 15:04:44 von
neuester Beitrag 08.12.23 08:44:17 von
neuester Beitrag 08.12.23 08:44:17 von
Beiträge: 6.419
ID: 1.218.035
ID: 1.218.035
Aufrufe heute: 2
Gesamt: 543.901
Gesamt: 543.901
Aktive User: 0
ISIN: CA64129Y1079 · WKN: A12GAQ
0,0055
EUR
0,00 %
0,0000 EUR
Letzter Kurs 13:00:30 Lang & Schwarz
Werte aus der Branche Dienstleistungen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,3000 | +128,07 | |
| 1,0100 | +60,32 | |
| 78,25 | +25,18 | |
| 1,6000 | +23,08 | |
| 30,00 | +18,81 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,1700 | -14,90 | |
| 6,5000 | -15,03 | |
| 1,1700 | -18,18 | |
| 0,8200 | -25,45 | |
| 9,3500 | -44,67 |
Beitrag zu dieser Diskussion schreiben
Feedback
"Last week, the Drug Enforcement Administration's (DEA) made a decision in the long-anticipated rescheduling of CBD following the Federal Drug Administration's (FDA) approval of GW Pharmaceutical's FPP, Epidiolex, for the treatment of seizures associated with two forms of epilepsy.
The DEA announced that the FDA-approved drug Epidiolex will be rescheduled in Schedule V from Schedule I,
"Epidiolex contains cannabidiol (CBD), a chemical constituent of the cannabis plant (commonly referred to as marijuana). The CBD in Epidiolex is extracted from the cannabis plant and is the first FDA-approved drug to contain a purified extract from the plant."
This is incredibly significant as the DEA has recognized that CBD is amongst those substances that have a low potential for abuse and health benefits, as compared with Schedule I substances, which have no currently accepted medical use in the United States, a lack of accepted safety for use and a high potential for abuse. By rescheduling CBD to Schedule V, the DEA has recognized the benefits of API-grade CBD and its low potential for abuse.
Given that the FDA's approval and DEA's actions on Epidiolex have raised the visibility of hemp-derived CBD products, it is even more critical that the U.S. Congress passes the 2018 Hemp Farming Act to permanently establish hemp and hemp-derived products as agricultural commodities in the United States."
und dass dann verstehen in Zusammenhang mit:
"INTRODUCING
nu.thc™ & nu.cbd™
nu.thc™ & nu.cbd™ are healthy, sugar-free cannabinoid tablets that offer a metered dose of THC/CBD, combined with the increased bioavailability and powerful antioxidant properties of pterostilbene. Each tablet contains 125mg of our patented pterostilbene (the same amount found in 25,000 raw blueberries). nu.thc™ & nu.cbd™ Chewable Tablets represent a market first and are the only commercially ready tablets of its kind."
The DEA announced that the FDA-approved drug Epidiolex will be rescheduled in Schedule V from Schedule I,
"Epidiolex contains cannabidiol (CBD), a chemical constituent of the cannabis plant (commonly referred to as marijuana). The CBD in Epidiolex is extracted from the cannabis plant and is the first FDA-approved drug to contain a purified extract from the plant."
This is incredibly significant as the DEA has recognized that CBD is amongst those substances that have a low potential for abuse and health benefits, as compared with Schedule I substances, which have no currently accepted medical use in the United States, a lack of accepted safety for use and a high potential for abuse. By rescheduling CBD to Schedule V, the DEA has recognized the benefits of API-grade CBD and its low potential for abuse.
Given that the FDA's approval and DEA's actions on Epidiolex have raised the visibility of hemp-derived CBD products, it is even more critical that the U.S. Congress passes the 2018 Hemp Farming Act to permanently establish hemp and hemp-derived products as agricultural commodities in the United States."
und dass dann verstehen in Zusammenhang mit:
"INTRODUCING
nu.thc™ & nu.cbd™
nu.thc™ & nu.cbd™ are healthy, sugar-free cannabinoid tablets that offer a metered dose of THC/CBD, combined with the increased bioavailability and powerful antioxidant properties of pterostilbene. Each tablet contains 125mg of our patented pterostilbene (the same amount found in 25,000 raw blueberries). nu.thc™ & nu.cbd™ Chewable Tablets represent a market first and are the only commercially ready tablets of its kind."
Antwort auf Beitrag Nr.: 58.846.461 von techinvestor69 am 01.10.18 21:48:50Wir werden es sehen.
$NU ist m.M.n. ein solides Play.
EAT hab ich mich kaum mit befasst.
$NU ist m.M.n. ein solides Play.
EAT hab ich mich kaum mit befasst.
NSP.V heute +90 Prozent - ohne News.
Vielleicht liefern beide eine gemeinsame News ;-).
Produktionsstart zusammen mit EAT ist auch überfällig.
Vielleicht liefern beide eine gemeinsame News ;-).
Produktionsstart zusammen mit EAT ist auch überfällig.
Antwort auf Beitrag Nr.: 58.846.347 von techinvestor69 am 01.10.18 21:34:24Ja sieht gut aus!
Die Woche sollen News kommen....Mittwoch evtl.
https://twitter.com/3ngelsson/status/1046833107784159232
Die Woche sollen News kommen....Mittwoch evtl.
https://twitter.com/3ngelsson/status/1046833107784159232
Quelle: Twitter
Trading Spotlight
Antwort auf Beitrag Nr.: 58.732.549 von techinvestor69 am 18.09.18 22:18:56
+45% mit 8,5 Mio Volumen....und das ohne NEWS!!!!
Nur 13. Mio CAD Marktkapitalisierung....
günstigste Aktie in diesem Sektor..
Kursziel 0,50 Cad
Schau mer mal
+45% mit 8,5 Mio Volumen....und das ohne NEWS!!!!
Nur 13. Mio CAD Marktkapitalisierung....
günstigste Aktie in diesem Sektor..Kursziel 0,50 Cad
Schau mer mal
Ups falsche Thread...
Aurora übernimmt ICC Labs für 1,95 Cad pro Aktie 😳 wird leider nix mit meinem 5 cad Kursziel ....
https://technical420.com/cannabis-article/aurora-cannabis-ac…
https://technical420.com/cannabis-article/aurora-cannabis-ac…
Antwort auf Beitrag Nr.: 58.178.303 von new_investor am 10.07.18 15:16:33Verkaufsstart im laufenden Quartal in 400 Apotheken.....
As of July 11th, 2018, NeutriSci and Nutritional High will commence the production process of its newly developed chewable, sublingual THC product (“Nu Energy Tablets”) for sale and distribution in the state of California. The Nu Energy Tablets will be produced at the Company’s Pasa Verde manufacturing facility, located in Sacramento, California. Delivery of the first purchase orders is on track and set to begin in Q3 of 2018. Initial distribution will begin in approximately 400 dispensaries across the state.
Schau mer mal
As of July 11th, 2018, NeutriSci and Nutritional High will commence the production process of its newly developed chewable, sublingual THC product (“Nu Energy Tablets”) for sale and distribution in the state of California. The Nu Energy Tablets will be produced at the Company’s Pasa Verde manufacturing facility, located in Sacramento, California. Delivery of the first purchase orders is on track and set to begin in Q3 of 2018. Initial distribution will begin in approximately 400 dispensaries across the state.
Schau mer mal
Durchsuchen
